Home
RVMD
RVMD News

Latest Revolution Medicines Inc. (RVMD) News on October 23, 2025

Revolution Medicines, Inc. (RVMD) Insider Sells Shares

Insider Monkey

20 days ago

Revolution Medicines, Inc. (RVMD) Insider Sells Shares

Morning Movers: Kroger rises following second quarter results

TipRanks

a month ago

Morning Movers: Kroger rises following second quarter results

Revolution Medicines (RVMD) Announces Promising Phase 1 Daraxonrasib Clinical Trial Results

Simply Wall St.

a month ago

Revolution Medicines (RVMD) Announces Promising Phase 1 Daraxonrasib Clinical Trial Results

Revolution’s daraxonrasib moves to Phase III after PDAC hat-trick

Clinical Trials Arena

a month ago

Revolution’s daraxonrasib moves to Phase III after PDAC hat-trick

MT Newswires

a month ago

Wedbush Raises Price Target on Revolution Medicines to $77 From $73, Keeps Outperform Rating

MT Newswires

a month ago

Revolution Medicines Unveils Positive Data to Launch Phase 3 Pancreatic Cancer Trial

Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma

GlobeNewswire

a month ago

Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma

Revolution Medicines (RVMD) Is Up 6.7% After Truist’s Bullish Initiation Is the Pipeline Rethink Underway?

Simply Wall St.

a month ago

Revolution Medicines (RVMD) Is Up 6.7% After Truist’s Bullish Initiation Is the Pipeline Rethink Underway?

MT Newswires

2 months ago

Truist Initiates Revolution Medicines at Buy With $99 Price Target

Oppenheimer Reaffirms Outperform on Revolution Medicines (RVMD) Amid RAS Therapy Progress

Insider Monkey

2 months ago

Oppenheimer Reaffirms Outperform on Revolution Medicines (RVMD) Amid RAS Therapy Progress

MT Newswires

4 months ago

Wedbush Lifts Price Target on Revolution Medicines to $73 From $67, Keeps Outperform Rating

MT Newswires

4 months ago

Revolution Medicines Signs $2 Billion Funding Deal With Royalty Pharma

Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers

GlobeNewswire

4 months ago

Revolution Medicines Enters Into $2 Billion Flexible Funding Agreement with Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for Patients with RAS-Addicted Cancers

MT Newswires

4 months ago

Sector Update: Health Care Stocks Mixed in Afternoon Trading

MT Newswires

4 months ago

Revolution Medicines Says FDA Grants Daraxonrasib Breakthrough Therapy Designation

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations

GlobeNewswire

4 months ago

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations

This Revolution Medicines Insider Increased Their Holding In The Last Year

Simply Wall St.

4 months ago

This Revolution Medicines Insider Increased Their Holding In The Last Year

First subject dosed in Revolution Medicines’ Phase III NSCLC treatment trial

Clinical Trials Arena

5 months ago

First subject dosed in Revolution Medicines’ Phase III NSCLC treatment trial

MT Newswires

5 months ago

Revolution Medicines Doses First Patient in Late-Stage Trial Evaluating Daraxonrasib to Treat Lung Cancer

Revolution Medicines Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung Cancer

GlobeNewswire

5 months ago

Revolution Medicines Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung Cancer

We Think Revolution Medicines (NASDAQ:RVMD) Can Afford To Drive Business Growth

Simply Wall St.

5 months ago

We Think Revolution Medicines (NASDAQ:RVMD) Can Afford To Drive Business Growth

Thomson Reuters StreetEvents

5 months ago

Q1 2025 Revolution Medicines Inc Earnings Call

Revolution Medicines Inc (RVMD) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ...

GuruFocus.com

5 months ago

Revolution Medicines Inc (RVMD) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ...

MT Newswires

6 months ago

Revolution Medicines Q1 Net Loss Widens

Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress

GlobeNewswire

6 months ago

Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress

Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025

GlobeNewswire

6 months ago

Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025

MT Newswires

6 months ago

Sector Update: Health Care Stocks Swing Between Small Gains, Losses

MT Newswires

6 months ago

Revolution Medicines Shares Rise on 'Encouraging' Phase 1 Lung Cancer Trial Data

Why Is Cancer Drug Developer Revolution Medicines Stock Trading Higher On Monday?

Benzinga

6 months ago

Why Is Cancer Drug Developer Revolution Medicines Stock Trading Higher On Monday?

Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting

GlobeNewswire

6 months ago

Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting

Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

GlobeNewswire

7 months ago

Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Revolution Medicines (RVMD): The Best Debt Free Mid Cap Stock to Buy Now

Insider Monkey

7 months ago

Revolution Medicines (RVMD): The Best Debt Free Mid Cap Stock to Buy Now

Revolution Medicines to Participate in April 2025 Investor Conferences

GlobeNewswire

7 months ago

Revolution Medicines to Participate in April 2025 Investor Conferences

Is Revolution Medicines (RVMD) the Best Mid Cap Biotech Stock to Buy?

Insider Monkey

7 months ago

Is Revolution Medicines (RVMD) the Best Mid Cap Biotech Stock to Buy?

Is Revolution Medicines, Inc. (RVMD) Among Stocks With At Least $20 Million In Insider Spending Recently?

Insider Monkey

8 months ago

Is Revolution Medicines, Inc. (RVMD) Among Stocks With At Least $20 Million In Insider Spending Recently?

Revolution Medicines, Inc. (RVMD): Among the Cash-Rich Mid Cap Stocks to Buy Now

Insider Monkey

8 months ago

Revolution Medicines, Inc. (RVMD): Among the Cash-Rich Mid Cap Stocks to Buy Now

Thomson Reuters StreetEvents

8 months ago

Q4 2024 Revolution Medicines Inc Earnings Call

Revolution Medicines Inc (RVMD) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...

GuruFocus.com

8 months ago

Revolution Medicines Inc (RVMD) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...

MT Newswires

8 months ago

Revolution Medicines Q4 Net Loss Narrows

Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress

GlobeNewswire

8 months ago

Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress

Earnings To Watch: Revolution Medicines Inc (RVMD) Reports Q4 2024 Result

GuruFocus.com

8 months ago

Earnings To Watch: Revolution Medicines Inc (RVMD) Reports Q4 2024 Result

Revolution Medicines to Participate in March 2025 Investor Conferences

GlobeNewswire

8 months ago

Revolution Medicines to Participate in March 2025 Investor Conferences

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025

GlobeNewswire

8 months ago

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2024 After Market Close on February 26, 2025

Does Revolution Medicines (RVMD) Have the Potential to Rally 74.05% as Wall Street Analysts Expect?

Zacks

8 months ago

Does Revolution Medicines (RVMD) Have the Potential to Rally 74.05% as Wall Street Analysts Expect?

Why Revolution Medicines, Inc. (RVMD) Is Among the Best Healthcare Stocks To Buy According to Analysts

Insider Monkey

8 months ago

Why Revolution Medicines, Inc. (RVMD) Is Among the Best Healthcare Stocks To Buy According to Analysts

Is Revolution Medicines, Inc. (NASDAQ:RVMD) Trading At A 49% Discount?

Simply Wall St.

9 months ago

Is Revolution Medicines, Inc. (NASDAQ:RVMD) Trading At A 49% Discount?

Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference

GlobeNewswire

9 months ago

Revolution Medicines to Participate in the Guggenheim Securities SMID Cap Biotech Conference

Keros Therapeutics (KROS) Soars 5.1%: Is Further Upside Left in the Stock?

Zacks

9 months ago

Keros Therapeutics (KROS) Soars 5.1%: Is Further Upside Left in the Stock?

Is Revolution Medicines, Inc. (RVMD) the Best Russell 2000 Stock to Invest in According to Analysts?

Insider Monkey

9 months ago

Is Revolution Medicines, Inc. (RVMD) the Best Russell 2000 Stock to Invest in According to Analysts?

Revolution Medicines, Inc. (RVMD): The Biotech Stock with Biggest Upside Potential

Insider Monkey

9 months ago

Revolution Medicines, Inc. (RVMD): The Biotech Stock with Biggest Upside Potential

Down -7.83% in 4 Weeks, Here's Why Revolution Medicines (RVMD) Looks Ripe for a Turnaround

Zacks

9 months ago

Down -7.83% in 4 Weeks, Here's Why Revolution Medicines (RVMD) Looks Ripe for a Turnaround

Revolution Medicines (RVMD) Loses -7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks

9 months ago

Revolution Medicines (RVMD) Loses -7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

MT Newswires

9 months ago

UBS Adjusts Price Target on Revolution Medicines to $71 From $65, Keeps Buy Rating

Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

10 months ago

Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference

One Revolution Medicines Insider Raised Their Stake In The Previous Year

Simply Wall St.

10 months ago

One Revolution Medicines Insider Raised Their Stake In The Previous Year

MT Newswires

a year ago

Wedbush Cuts Price Target on Revolution Medicines to $67 From $70, Keeps Outperform Rating

MT Newswires

a year ago

Revolution Medicines Closes Offering of 16.6 Million Shares

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire

a year ago

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

Revolution Medicines price target raised to $87 from $82 at Guggenheim

TipRanks

a year ago

Revolution Medicines price target raised to $87 from $82 at Guggenheim

MT Newswires

a year ago

Revolution Medicines Prices $45 Million Stock, Warrant Offering

Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire

a year ago

Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants

MT Newswires

a year ago

Revolution Medicines Launches $600 Million Offering of Common Shares

Revolution Medicines Announces Commencement of Public Offering of Common Stock

GlobeNewswire

a year ago

Revolution Medicines Announces Commencement of Public Offering of Common Stock

MT Newswires

a year ago

Stifel Raises Price Target on Revolution Medicines to $80 From $70, Maintains Buy Rating

MT Newswires

a year ago

Revolution Medicines Reports Early Data Supporting Ongoing Study of Cancer Therapies

Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio

GlobeNewswire

a year ago

Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio

Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024

GlobeNewswire

a year ago

Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024

Decoding Revolution Medicines Inc (RVMD): A Strategic SWOT Insight

GuruFocus.com

a year ago

Decoding Revolution Medicines Inc (RVMD): A Strategic SWOT Insight

MT Newswires

a year ago

Revolution Medicines Q3 Loss Narrows; Reaffirms Full-Year Guidance

Revolution Medicines Inc (RVMD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...

GuruFocus.com

a year ago

Revolution Medicines Inc (RVMD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...

Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress

GlobeNewswire

a year ago

Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress

MT Newswires

a year ago

Revolution Medicines Insider Sold Shares Worth $3,878,773, According to a Recent SEC Filing

Revolution Medicines to Participate in Upcoming Investor Conferences

GlobeNewswire

a year ago

Revolution Medicines to Participate in Upcoming Investor Conferences

Revolution Medicines Inc (RVMD) Q3 2024 Earnings Report Preview: What To Look For

GuruFocus.com

a year ago

Revolution Medicines Inc (RVMD) Q3 2024 Earnings Report Preview: What To Look For

Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024

GlobeNewswire

a year ago

Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024

MT Newswires

a year ago

Revolution Medicines Says Potential Pancreatic Cancer Treatment Shows 'Encouraging' Initial Results

Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

GlobeNewswire

a year ago

Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

GlobeNewswire

a year ago

Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

MT Newswires

a year ago

Revolution Medicines Doses First Patient in Phase 3 Study of Pancreatic Cancer Drug

Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma

GlobeNewswire

a year ago

Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma

MT Newswires

a year ago

Revolution Medicines Insider Sold Shares Worth $824,804, According to a Recent SEC Filing

MT Newswires

a year ago

Revolution Medicines Insider Sold Shares Worth $1,510,773, According to a Recent SEC Filing

MT Newswires

a year ago

Revolution Medicines Insider Sold Shares Worth $2,517,055, According to a Recent SEC Filing

Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast

GlobeNewswire

a year ago

Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast

MT Newswires

a year ago

Revolution Medicines Insider Sold Shares Worth $517,631, According to a Recent SEC Filing

MT Newswires

a year ago

89bio Appoints Teresa Perney as Chief Regulatory, Quality Officer

Revolution Medicines, Inc. (RVMD): Among Hedge Funds’ Top Biotech Stock Picks

Insider Monkey

a year ago

Revolution Medicines, Inc. (RVMD): Among Hedge Funds’ Top Biotech Stock Picks

MT Newswires

a year ago

Revolution Medicines Insider Sold Shares Worth $716,389, According to a Recent SEC Filing

Revolution Medicines First Half 2024 Earnings: US$1.51 loss per share (vs US$1.64 loss in 1H 2023)

Simply Wall St.

a year ago

Revolution Medicines First Half 2024 Earnings: US$1.51 loss per share (vs US$1.64 loss in 1H 2023)

Thomson Reuters StreetEvents

a year ago

Q2 2024 Revolution Medicines Inc Earnings Call

MT Newswires

a year ago

Revolution Medicines Q2 Loss Narrows

Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress

GlobeNewswire

a year ago

Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress

MT Newswires

a year ago

Revolution Medicines Insider Sold Shares Worth $458,827, According to a Recent SEC Filing

Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy?

Zacks

a year ago

Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy?

Revolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024

GlobeNewswire

a year ago

Revolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024

MT Newswires

a year ago

Barclays Adjusts Price Target on Revolution Medicines to $54 From $52, Maintains Overweight Rating

MT Newswires

a year ago

UBS Adjusts Price Target on Revolution Medicines to $65 From $40, Maintains Buy Rating

MT Newswires

a year ago

Revolution Medicines Insider Sold Shares Worth $1,576,322, According to a Recent SEC Filing

MT Newswires

a year ago

Needham Adjusts Revolution Medicines Price Target to $62 From $46, Maintains Buy Rating

MT Newswires

a year ago

HC Wainwright Raises Price Target on Revolution Medicines to $56 From $44, Maintains Buy Rating

Share on Social Networks: